Bioartificial liver treatment using hiHep cells after liver surgery
Part of Cancer, Digestive system clinical trials.
This early-stage study tests a lab-made “bioartificial liver” (using hiHep cells) after major liver surgery to help the remaining liver recover. It may help people whose remaining liver volume after resection is less than half and who have acceptable heart, lung, and blood test results for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a liver condition needing liver resection (like liver cancer or certain liver tumors or hepatolithiasis)
- Your liver function is in the Child A or Child B range
- You are expected to have less than 50% of your normal liver volume remaining after surgery
- You can safely have surgery based on heart and breathing checks
- You do not have serious brain bleeding or major late-stage brain symptoms
- You meet blood oxygen, blood clotting, and blood/platelet safety requirements for surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This study tests a treatment given before surgery for liver cancer that is at high risk of coming back. You would receive a combination of chemotherapy directly into the liver artery (HAIC), a targeted pill (lenvatinib), and an immunotherapy drug (a PD-1 inhibitor) — if a computer model predicts you might benefit.
This trial tests an experimental liver cell injection to see if it is safe and can help people with decompensated cirrhosis, a serious liver condition. If you qualify, you may receive this new treatment to potentially improve liver function.
This trial tests a new way to treat liver cancer by first transplanting part of a donor liver while keeping most of the original liver, then removing the remaining cancer later. It may help patients with liver cancer who need a transplant but have limited options.
This study tests a new bioartificial liver made from special cells to support people with severe liver problems, including liver failure or when the liver is too small after surgery. It aims to see if it is safe and can help the liver recover.
This trial tests a new way to control blood flow during laparoscopic liver surgery. It compares two methods to see which is safer and more effective for patients with certain liver conditions.
Hear when a new Hepatoma Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.